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Introduction: A Changing Landscape
Before the 1980s, most of the revenue for medical 
research conducted in the United States came from 
federal grants. Federal support of basic research 
led to the fi rst vaccines for the fl u, polio, and other 
childhood diseases. Other medical advances made 
with federal support include the discoveries of 
neurotransmitters in the brain, identifi cation of 
over 20 cancer–related genes, and demonstration 
that cholesterol levels are linked with potential 
heart attacks (United States Senate, 2000). Cancer 
treatment drugs such as Paclitaxel (Taxol, Bris-
tol–Meyers–Squibb, Princeton, NJ) have been 
developed and clinically tested in humans with 
funding from the National Cancer Institute (Nader 
& Love, 1993). Such federally supported research 
has been primarily conducted in prestigious aca-
demic medical centers such as the Mayo Clinic, 
Johns Hopkins, Sloan Kettering, Mt. Sinai, and 
MD Anderson, which are located in large, mostly 
urban communities.
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The world of clinical research has changed over 
the last 30 years. Federal funding for research has 
decreased and industry funding has steadily esca-
lated; by 1991, industry funding outpaced federal 
funding, and by 2000, 70% of clinical trials were 
funded by industry (Bodenheimer, 2000). Some 
industry research is focused on the development 
of new or novel drugs, but considerable industry 
effort is directed toward commercial interests such 
as extending patents, fi nding new uses for exist-
ing drugs, developing “me–too” drugs to secure a 
market share, and assessing prescription practices 
(Kottow, 2009). The change in the research venue 
is also notable; most clinical research has migrated 
to nonacademic environments. Although industry 
funding for clinical research has steadily increased 
(Congressional Budget Offi ce, 2006), the share of 
funding for such research conducted in academic 
medical centers declined from 80% in 1991 (Klein 
& Fleischman, 2002) to 35% in 2005 (Fisher, 2006), 
and the decline has continued (Fisher, 2006, 2007; 
Shuchman, 2007; Sox, 2001). Currently, most indus-
try research, including disease–specifi c studies as 
well as genetics and pharmacogenomics research, 
takes place in settings unaffi liated with academic 
medical centers, such as private physicians’ offi ces, 
research institutes, hospitals, and clinics (Chen, 
Miller, & Rosenstein, 2003; Klein & Fleischman, 
2002). Federally funded research, such as the Clini-
cal Trials Cooperative Group Program sponsored 
by the National Cancer Institute, is also moving 
to community–based settings (National Cancer 
Institute, 2009).
As the world of clinical research has evolved, so 
too have the regulatory approaches for protecting 
those who become research subjects. Institutional 
review boards (IRBs) serve as key oversight bodies 
for monitoring research that involves human par-
ticipants. They are charged with evaluating the risks 
and benefi ts, subject selection methods, informed 
consent process, and methods for protecting privacy 
and confi dentiality. At one time, institutions relied 
primarily on the work of their own institutionally 
supported IRBs to fulfi ll these oversight responsi-
bilities. As a result of recent changes in the structure, 
setting, and funding of clinical research, although 
many institutions still retain their own IRBs, new 
models such as independent IRBs (Macklin, 2008), 
community hospital IRBs (Hall et al., 2009), and 
community–based IRBs now perform oversight 
functions (Jansen, 2005). Many clinical studies that 
are approved by independent IRBs are conducted in 
multiple sites and in multiple states (Christensen & 
Orlowski, 2005). Even institutions that retain their 
own IRBs may choose to submit certain kinds of 
studies to other IRBs rather than performing an 
in–house review.
Although a robust literature base explores the 
ethical, legal, and regulatory challenges associ-
ated with the protection of human subjects, there 
is a growing sense that, as Michael Kottow (2009) 
cautions, “the agility of biomedical research far 
outstrips the pace of research ethics.” He is not 
alone in his concerns. In an effort to keep pace with 
the changing times, the U.S. Department of Health 
and Human Services (HHS) has launched a process 
to revise the Common Rule. On July 26, 2011, HHS 
issued an advance notice of proposed rulemaking 
(ANPRM) to solicit public comments on “how 
current regulations for protecting human subjects 
who participate in research might be modernized 
and revised to be more effective” (U.S. HHS, 2011). 
The intent behind the rulemaking involves efforts 
to both enhance protections for subjects and reduce 
delay and burden for investigators. Section IV of 
the ANPRM focuses on efforts to improve informed 
consent and determine what a person needs to 
know to make an enlightened decision to enroll in 
a research study. This section highlights a number 
of broad concerns about current requirements for 
informed consent forms. For example, question 40 
of the ANPRM specifi cally asks whether informed 
consent would be improved if regulations included 
additional requirements regarding the consent 
process and, if so, what should be required. The 
comments submitted to HHS become part of the 
public record. Lodged primarily by researchers 
and institutional representatives, these comments 
provide an indication of evolving perspectives 
within the scientifi c community. All submitted 
comments, along with the name of the commenter, 
can be viewed online (U.S. HHS, 2011).
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Given the changing research environment, it 
seems useful to examine the perspectives that both 
“the protectors and the protected” bring to the 
discussion about informed consent and specifi cally 
the kinds of information most important to include 
in consent forms. This commentary fi rst discusses 
the fi ndings that emerged from two studies: an 
exploration of the decision–making processes used 
by members who serve on different kinds of IRBs 
(Cook & Hoas, 2011a, b) and an exploration of the 
decision–making processes employed by research 
participants (Cook & Hoas, 2011c). This discussion 
sheds light on IRB members’ deliberations when 
reviewing research protocols and the values, needs, 
and experiences of the research participants. It 
then presents some of the comments submitted to 
the ANPRM process in an effort to appreciate the 
range of opinions within the research community 
and highlight areas where there may be a lack of 
agreement about what may be needed to optimize 
the protection of human subjects.
Research Methodology
The IRB study and the Research Participant study 
were funded by the National Science Foundation. 
Both studies were inductive and contextual in 
nature (Miles & Huberman, 1994; Strauss & Corbin, 
1990), an approach well–suited to the exploration 
of these complex phenomena and relationships. 
The studies analyze key informant interviews with 
IRB members and research participants who live 
in rural and urban settings. The sampling strategy 
was designed to maximize respondent variation 
to facilitate examination of information–rich cases, 
detect patterns spanning differences within and 
among the various stakeholder cohorts and settings, 
and optimize confi dentiality. To create a national 
sample for the IRB study, the investigators fi rst 
identifi ed all IRBs holding a Federal–Wide Assur-
ance Number from the Offi ce of Human Research 
Protections. IRBs were categorized according to 
type, and a purposive sample was selected so as to 
include seven groups or types: IRBs that serve in 
universities with and without medical schools, IRBs 
from both rural and urban hospitals, community 
IRBs from both rural and urban communities, and 
for–profi t IRBs that typically serve researchers in 
several states. Once selected, the IRB was contacted 
via phone or email, and a member was invited to 
participate in the study. A minimum of four to six 
key informants were selected from each type of IRB 
for a total of 40 participants.
To obtain a national sample of research partici-
pants, the investigators designed a geographically 
diverse sample of facilities that engage in health 
research, including hospitals, clinics, mental health 
centers, and private practice settings. Healthcare 
personnel were contacted, given information about 
the study, and asked to verbally share information 
about the study with patients or post information 
about the study in their facilities. Persons interested 
in participating could then contact the investigators 
and schedule an interview. The sample of research 
participants was composed of 33 females and 17 
males. The education level of participants was high 
with 87% reporting at least some college education. 
After conducting 50 interviews, no new information 
was emerging; it was determined that saturation 
had been achieved and the interview process was 
suspended.
For both studies, the investigators used semis-
tructured instruments that employed core questions 
while also allowing for exploration of unanticipated 
or emerging issues. The interviews were conducted 
by phone and transcribed verbatim. Most inter-
views lasted about an hour. With the aid of Atlas.ti 
software, the data were coded and organized into 
themes that could then be compared and contrasted. 
This approach allowed the investigators to obtain 
“yes” and “no” responses that could be calculated 
as well as lengthy explanations that showcased 
the processes for making decisions. Throughout 
the manuscript, representative quotes are used to 
provide a general view of the interviewees’ perspec-
tives. The interview data obtained from these stud-
ies provide a rich repository of insights from those 
who serve in a regulatory function (IRB members) 
and those for whom the regulations are designed 
to protect (human research subjects). Although 
the authors’ prior publications detail each study’s 
research methodology and overall fi ndings, this 
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article combines, compares, and contrasts key fi nd-
ings and themes of those two studies. By juxtapos-
ing the words and phrases of those who protect (IRB 
members) and of those who are protected (research 
participants), the article attempts to expand aware-
ness and appreciation of where we are and what it 
might take to foster a system that truly optimizes 
protection of human subjects through the consid-
eration of all voices and concerns.
Protecting Subjects’ Rights and Welfare
The IRB Perspective
The fi ndings from the IRB study suggest that IRB 
members view their responsibility to protect the 
rights and welfare of human subjects in a very 
serious light. Indeed, members of all types of 
IRBs—academic, hospital, community/tribal, and 
independent—often described their IRB service as 
a “calling” and as a “mission.” Members from all 
types of IRBs frequently referenced the ethical vio-
lations of past studies like Tuskegee and the need 
to ensure such ethical deviations do not re–occur. 
Most IRB members described their IRB service as 
very time intensive, often unappreciated, and at 
times burdensome, but also very important; they 
reported that the numbers of studies under review 
were increasing, study protocols were often com-
plicated, and the decisions they made infl uenced 
research conducted in diverse rural and urban 
populations. Members reported that many hours 
were expended in the process of carefully reading 
the materials submitted to the IRB and attending 
the scheduled meetings. Although the work was 
described as challenging and diffi cult, all of the 
members spoke of its importance and reported that 
their IRBs “do a good job” (Cook & Hoas, 2011a, b).
However, the fi ndings from the IRB study also 
suggested that—despite members’ commitment, 
good intentions, and hard work—efforts to protect 
human subjects may fall short of the mark. Most 
IRBs used, as a central strategy for optimizing 
the protection of human subjects, careful scrutiny 
and management of the informed consent form. 
The data showed that this strategy was pursued 
regardless of the type of IRB. A quote representative 
of this approach was offered by an IRB member 
who explained: “The focus is on the form. [There 
is] little discussion of the context or the process” 
(academic IRB). Most IRB members viewed the 
form as an essential tool for ensuring a voluntary 
and enlightened participant. Explained one IRB 
member: “Our process is, fi rst it’s the member 
being able to understand, then from the staff point 
of view, and then we go over it point by point. You 
can have a good reading level, but not represen-
tation of what is going to happen” (independent 
IRB). Members from other types of IRBs detailed 
similar approaches to ensure that the form met 
all technical and regulatory requirements. They 
offered statements such as: “[IRBs] nitpick every 
single word throughout the 35 pages” (medical 
school IRB); and “I don’t think we have had hardly 
a form that hasn’t been altered to go to a lower level 
of readability” (community IRB); and “We strive 
for understandability and we look for medical 
jargon . . . we have members who are sticklers” 
(community IRB).
The need to create a consent document that 
clearly conveys essential information was evi-
denced when members talked about issues such as 
assessing risk and benefi t. Members offered repre-
sentative quotes: “So it is the role of the IRB to see 
risks and benefi ts and catch risks. With the help of 
committee members that are knowledgeable about 
stuff, they catch potential risk and we make changes 
to the consent form” (medical school IRB). This 
approach seems to refl ect an understanding that 
the IRB’s job is not to design the research study, but 
to recognize risk and make certain it is accurately 
conveyed. The following quote sheds light on this 
perspective: “It is not the job of the IRB to change 
the study. The IRB’s job is to make sure participants 
have the best chance of understanding the risks” 
(hospital IRB). As another member explained, 
“I am not sure how you quantify extent but it is 
not unusual for us to clarify, tighten, amplify the 
consent form. I am not sure that we see something 
that wasn’t in the materials as much as clarify and 
bring it out and clean it up and better convey, make 
it more understandable” (academic IRB).
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IRB members acknowledged the challenge of 
developing a consent form that contains all man-
dated information while still meeting a reading 
competency level that seemed to be envisioned as 
somewhere between 4th and 9th grades. Tensions 
arise with investigators and sponsors who perceive 
such scrutiny—and often requirements for word–
by–word changes—as intrusive and a hindrance to 
study approval. IRB members acknowledged that 
the approved forms were probably too long and 
might not be read by research participants. Mem-
bers asserted, however, that such careful scrutiny 
was essential in terms of documenting their regula-
tory obligations to protect human subjects. The form 
was seen as a way to underscore the considerable 
efforts undertaken to ensure that decisions of par-
ticipants were both voluntary and informed.
In addition to careful management of the con-
sent form, members also explained that they care-
fully evaluated any compensation provided to the 
research participant to minimize risks of compen-
sation becoming coercive or unduly infl uencing a 
decision to participate. Indeed, all of the members 
felt they had suffi cient guidance and authority to 
deal with the topic of participant compensation. As 
one member explained, “When I see participants 
are going to be paid, that is always a fl ag to talk 
about coercion and incentives, especially if it is a 
vulnerable population” (community IRB). Another 
reported: “Sometimes we hear they want to give a 
big bonus and we won’t let them do that” (academic 
IRB). IRB members explained that they were so 
vigilant about participant compensation because 
they wanted to ensure that potential participants 
truly understood and appreciated the risks associ-
ated with participating in research and would not 
be swayed by the prospect of compensation.
The Participant Perspective
Most of the participants (42 of 50) interviewed for 
this study reported that they read the informed 
consent document before enrolling, and most 
reported that they had been fully informed (Cook 
& Hoas, 2011a, b). Few participants reported nega-
tive experiences with the informed consent process; 
most seemed to view the process as routine or as 
what one could reasonably expect from a medical 
encounter in a professional setting. As one partici-
pant stated, “It had a good setting, good informa-
tion. She slipped out and let me read it and came 
back and asked if I had questions” (participant 6).
A series of follow–up questions, however, call 
into question the extent to which participants truly 
understood and appreciated the purpose of the 
consent form, the information it contained, or what 
it meant to participate in a research study. The data 
suggest that participants’ beliefs and expectations 
about healthcare may make it diffi cult for them 
to absorb key information when trying to make 
informed decisions about participating in research. 
Rather than relying on information provided via the 
consent process or the consent form, participants 
seemed to make their decisions based on the belief 
that participation would serve their best interests. 
Other factors that infl uenced decision making 
include beliefs about the trust, skill, and intent of 
those who conduct research, the legitimacy of the 
setting, and the socially meritorious purpose of 
the research. When patients were asked “Why did 
you enroll in the study?”, they uniformly reported 
that they trusted their doctors and believed that 
respected, trusted, and skilled clinicians would 
not suggest enrollment in a clinical trial unless it 
provided the best option for their care. When asked, 
“Who invited you to participate?”, participants 
typically referenced the involvement of personal 
physicians. Said one participant, “My oncolo-
gist. . . . He said ‘Hang on a second.’ He said you 
are perfect candidate for [this] study” (participant 
43). Other representative comments include: “My 
physician suggested it. He is the one that does it” 
(participant 46); and “[The] doctor who recruited 
me. I trust him completely and I love the man” 
(participant 14). Such trust and confi dence in the 
persons conducting the research seemed to limit the 
extent to which participants could seriously discern 
the difference between research and treatment or 
evaluate statements about the risks and benefi ts of 
research participation.
In addition to mentioning the confidence 
entrusted in one’s clinician, participants consistently 
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explained that a professionally recognized site—like 
a hospital, clinic, or physician’s offi ce—reinforced 
their assessment of legitimacy and potential benefi t. 
As one participant offered when asked to describe 
what information was most helpful in terms of mak-
ing a decision about research participation, “Well, 
I think it was because it was credible. It wasn’t just 
a piece of paper. It was in the hospital’s surgical 
setting. It was not just something in the mall. And 
it seemed like there was a benefi t and [he] would 
get more attention. And it was in the hospital” (par-
ticipant 10). Others explained: “I guess having gone 
in there and if it had been shady—I would have 
thought twice. But it was a nice, clean, presentable 
place. The professional manner and they were thor-
ough and they had the patient rights information. It 
looked like a doctor’s offi ce. They had all the things 
that I expect from a doctor’s offi ce” (participant 3); 
and “We went out to their offi ce and it was profes-
sional. It didn’t look like a store front. They had 
coffee and candy bars and they sit down and talk 
to you—from the receptionist, nurse, PA or NP, it 
was all nice. I met with three people during the fi rst 
visit” (participant 18).
Most participants also expressed support for 
and confi dence in the important work of science, 
generally believing that medical studies were 
designed and conducted to benefi t both the patient 
and humankind. Thus, in addition to providing 
personal benefi t to one who enrolls, most partici-
pants also alluded to the benefi ts gained for society, 
and described hopes that research would fi nd new 
cures, create miracle drugs, and reduce suffering 
in generations to come. They spoke of advances 
that had been made such as the polio vaccine and 
the treatments for AIDS and cancer. Representative 
quotes included: “I saw it as an obligation and it 
may have benefi ts to someone else” (participant 6); 
and “The other reason was very strong in my mind 
was maybe I would be doing something positive 
for science and for people. I would contribute. That 
was big in my mind” (participant 14); and “Just to 
be helpful, to help these peoples’ plight and further 
the research” (participant 37).
Given this multilayered trust that the par-
ticipants found in the person, the place, and the 
purpose of research, most seemed disinclined to 
seriously examine key information in the consent 
form including the statements of benefi ts and risks. 
This was evident when persons responded to a 
series of questions about risks and benefi ts includ-
ing: “What did you see as the benefi ts of participat-
ing, what did you see as the risks of participating 
and did you see the benefi ts as outweighing the 
risks?” When describing their assessment of the 
risks and benefi ts of participation, most explained 
that the benefi ts outweighed the risks. The data 
suggest that those who had enrolled in a clinical 
research study typically overestimated the benefi ts 
of participation, noting that it afforded “optimal 
personal care” and access to what would become 
the “new gold standard.” Participants offered 
representative statements like: “Well more for less. 
Better care and a better cure. My treatment would 
be more complete and there would be less chance of 
reoccurrence” (participant 47). Another participant 
reported: “By the time I met with the oncologist and 
told him I would join, I felt that the whole consent 
thing had been much ado about nothing. I would 
either get the gold standard or something they 
thought was even better. It sounded like a way I 
could give back with no real risk at all” (partici-
pant 49). This perception of personal benefi t was 
evidenced by another participant who explained: 
“Well, then I started talking myself into it and he 
[my doctor] said the D–drug would be the new Lipi-
tor, the miracle drug. That sounds so hopeful. . . . 
So I thought well if it works, I would be right in 
line and fi rst to get the full treatment” (participant 
14). The provision of more time and more tests was 
often cited as a validation that, upon enrolling in a 
study, one would receive better care.
The risk statements outlined on the consent 
forms were generally discounted even when such 
statements outlined the potential for serious com-
plications. Participants often explained: “I did not 
see any risks.” Many of those who discounted the 
risk statements on the consent forms believed that 
a study would not be offered by a trusted source, 
like one’s personal physician, unless the risks were 
minimal. This perspective was shown by statements 
like: “Because I don’t presume there are any risks. 
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They didn’t really talk about them” (participant 38); 
and “At the time, I didn’t see it as a risk because I 
didn’t even think to ask. . . . And I didn’t think about 
it then. I don’t remember that I was alerted to any 
problems. I probably wasn’t because I maybe would 
have hesitated if I had been alerted” (participant 
16). Some participants expressed the belief that the 
government would not allow studies—and doctors 
would not recommend them—if there were serious 
risks. As one participate explained: “But I think 
there is an assumption that you make in a way—
that if someone asks you to do this, like if a medical 
persons asks you—you think they already know the 
risks are minimal and they would not put you at 
a great deal of risk. They have your well–being at 
heart. That is how most people would think. But it 
may not be true. They are doctors. There is the trust 
thing” (participant 21).
Even when participants reported that the consent 
form identifi ed potential risks, they were not sure 
how to assess the importance or relevance of that 
information to their personal care. A representa-
tive comment is shown by the participant who 
explained: “I didn’t see many risks. The only thing 
that made it sound like any risk was the blood 
thinner and maybe you would be less inclined to 
stop bleeding—or maybe you could lose a lot of 
blood?” (participant 2). Another explained: “You 
had to sign a form that said you might have a heart 
attack. I thought it was a formality—like what you 
sign before surgery, the form saying you might 
die. It was just like the legal language thing on the 
consent forms . . . that thing you have on consent 
forms like being injured. Yeah. I didn’t take it seri-
ously” (participant 4). One person noted that the 
consent form did, in fact, indicate the potential 
risk of congestive heart failure, but was reassured 
when “the doctor said congestive heart failure was 
treatable” (participant 47).
Although consent forms are usually required to 
include institutional boilerplate information about 
protocols for privacy and confi dentiality, most par-
ticipants seem to lack a framework for appreciating 
why those safeguards are required and essential. 
Thus, this information was also generally disre-
garded. Participants expressed few concerns about 
privacy, confi dentiality, anonymity, and evolving 
issues like banking of blood and tissue samples 
and the potential uses of genetic information. Most 
did not seem to make distinctions between privacy, 
confi dentiality, and anonymity. Nearly all of the 
participants (42 of 50) believed that the standards 
for protection of participants were in place, that 
medical information was secure, and that their 
interests and well–being were protected. Explaining 
their understanding of privacy and confi dentiality, 
participants offered statements like: “It was private. 
I was the only one. I was the only one in the room” 
(participant 7) and “Yes. They seem to be careful of 
how they are handling phone calls and the personal 
upfront interview” (participant 17). When partici-
pating in studies that gathered genetic information, 
participants were reassured about anonymity when 
told they would be de–identifi ed by a numbering 
system and offered explanations like: “I would be 
assigned a number—that seemed OK” (participant 
6). For many patients, concerns about confi dential-
ity and privacy simply did not seem important. This 
was shown by people who said: “Didn’t even con-
sider that” (participant 1) and “Yes [adequate pro-
tection]. But then I am not paranoid” (participant 
5) and “I did think it was OK. They are planning to 
do video and audio—I had fl eeting thoughts about 
medical records and this mental health problem 
being on a permanent record for my daughter. But I 
think everybody has a mental health issue—so I felt 
fi ne” (participant 15). Refl ecting on implications of 
participating in a study, a participant explained: “I 
have no knowledge of what happened to the data 
over time. And see, foolishly, I didn’t think about it” 
(participant 7). Others explained: “How can people 
possibly understand that?” (participant 6); and “I 
think I gave them permission to use information 
about me” (participant 33).
The Role of Researcher Compensation 
and Other Commercial Considerations
The IRB Perspective
To use a colloquialism, IRB members seem adept 
at “looking where the light shines.” Members 
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noted that the regulatory guidance for issues like 
the content of the informed consent document and 
protocols for reviewing participant compensation 
are well developed, and IRBs feel competent to 
make decisions in such areas. IRB members found 
it more diffi cult, however, to resolve an array of 
other issues that infl uence their approach to review 
and, ultimately, the extent to which IRB efforts 
truly optimize the protection of human subjects. 
A key issue involves the core mission of the IRB, 
that is, whose interests should be served? When 
trying to explain how they approach their deci-
sions, members routinely noted that they faced 
convergent—and at times even competing—goals. 
Although the responsibility of protecting human 
subjects was uniformly acknowledged as a historic 
and key responsibility, IRB members consistently 
reported that they are also expected to support the 
interests of researchers/institutions and help to 
advance discoveries that benefi t society. Indeed, 
with the exception of one respondent who reported 
that protection of human subjects was the sole 
goal of the IRB, the other IRB members were very 
specifi c about the expectation and obligation to 
manage these additional goals. A representative 
comment about the need to support the interests 
of peer researchers was explained by a respondent 
who noted: “It is the dynamic. Like it is hard for 
doctors to turn one another down” (hospital IRB). 
Members described the important role that research 
fulfi lled within their institutions and the complica-
tions that could ensue if research was not approved. 
This was noted by a person who explained, “It can 
be hard to protest too much because the company is 
paying you. You are supposed to be thinking about 
the safety of the person but it is hard to divorce 
the idea of who is paying you” (independent IRB). 
Discerning the benefi ts that accrue to society was 
explained by one participant as a “grey zone, not 
in the patient’s best interests” but “maybe good in 
the long run?” (hospital IRB).
The formula for balancing what can be experi-
enced as three competing goals (protecting subjects, 
protecting the interests of researchers/institutions, 
and helping to advance discoveries) was not well–
defi ned. Members noted that confl icts among these 
goals can be hard to resolve and that approval of a 
study is generally based on a majority vote that may 
not refl ect the concerns of dissenting individuals. 
The tension encountered when trying to balance 
convergent goals was refl ected by comments such 
as: “I wish we could really protect. I think it [IRB] 
does primarily, except I am unhappy that the sub-
jects are not protected more” (hospital IRB). Another 
respondent explained: “There’s this tension. The 
doctors and the scientists will argue that the 
research is important. The community people might 
not like it and might feel that it is not really fair to 
the participants. So there is that tension” (academic 
IRB). The challenges that accompany the manage-
ment of “convergent goals” became apparent when 
IRB members described how they approached 
three increasingly diffi cult issues: Evaluation of 
the purpose of a study, disclosure and evaluation 
of researcher/institutional compensation, and 
obtaining awareness of participant needs, values, 
and expectations. These issues are challenging in 
part because they are not fully addressed by exist-
ing federal regulations or IRB member training. For 
example, some of the studies under review, mainly 
industry–funded studies, are designed to answer 
both scientifi c and commercial questions, such as 
development of a “me–too” drug or a change in 
formulary to extend a patent. The IRB members 
reported that a review generally focuses on the 
scientifi c approach, including the study design, 
research protocols, and related issues such as safety, 
risk, and effectiveness. Members may not know 
about the commercial purposes of a given study and 
indeed most noted a lack of regulations about their 
role when assessing the merit of studies that are 
designed primarily for commercial purposes. Mem-
bers reported that it was not clear whether the IRB 
should require submission of clear and transparent 
information about commercial purposes, if or how 
such purposes should infl uence the assessment of 
a study’s scientifi c merits, whether research partici-
pants should be informed of commercial purposes, 
or how commercial purposes should be evaluated 
when considering the study’s potential benefi ts to 
society. These kinds of issues brought to the fore 
the challenges posed by what was perceived, by 
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the vast majority of IRB members, as the need to 
manage convergent goals. Some suggested that an 
IRB’s exploration of commercial purposes could 
engender charges of “mission creep,” an issue of 
concern within their institutions or companies. 
Indicative of the tensions that can emerge when 
facing this less regulated area of review, members 
offered representative comments, such as, “Frankly, 
all of these bazillions of trials are a little tweaked 
because the patent is running out. All they want is 
to maintain the patent. So they tweak the drug a 
little bit, change the formularies or combinations 
a little, and then that will keep the patent in place. 
Should we tell the patients that? But the docs, the 
researchers say no. That’s not our business” (hos-
pital IRB). Another member noted, “We have had 
questions when people are a little uncomfortable 
about the science—like is this a good study? But 
there is some other committee that is supposed to 
look at the science—that is not our turf. So if it is 
not really benefi cial—like some kind of a patent 
study—we cannot really say much about that” 
(hospital IRB). The potential impact of disclosing 
and discussing a commercial purpose was sum-
marized by a member who noted: “It is like there is 
this fear [among researchers] that if you allow that 
kind of disclosure, the whole shebang will fall apart. 
People won’t join studies if you give them the whole 
truth. The trouble is how informed do people have 
to be? If the study was being conducted to extend a 
patent—I would not be willing to participate. And 
I would want to know that. Defi nitely. So there is 
intentional dishonesty in omitting information that 
could sway decisionmaking” (hospital IRB).
Although all IRB members reported that infor-
mation about the scientifi c purpose of a study was 
disclosed to the IRB, most IRB members reported 
that information about the commercial purpose of 
a study was not “on the table” (a descriptive often 
used by IRB members) during the review process. 
Indeed, members reported that they would not 
necessarily know if the study involved a commer-
cial purpose such as “tweaking the formulary” of 
an existing drug so as to extend a patent, develop-
ing a derivative drug to obtain a market share, or 
assessing prescription practices. Others noted that 
such issues would be recognized but simply not 
discussed. Some IRB members reported a nagging 
sense that certain kinds of studies were not neces-
sarily meritorious or truly benefi cial to society. 
Most noted, however, that any consideration of 
commercial purposes would remain “off the table” 
until regulatory guidance stipulates otherwise. 
There seemed to be a sense, among most IRB 
members, that existing regulations create a fl oor 
and a ceiling, leaving limited room for movement. 
This status seemed to leave some members with 
an uncomfortable and unresolved moral burden. 
As one noted, “You get everything approved if you 
wait long enough. Especially phase IV marketing: 
It’s a lousy drug that sells tremendously well and 
has nothing to do with science and it is declared as 
research and . . . the physician likes the new drug 
and starts prescribing it. This marketing is a very 
large part of the studies for our IRB. You become a 
cooperator” (independent IRB).
Most IRB members also reported a lack of 
guidance about researcher and institutional com-
pensation, noting that it was unclear what should 
be disclosed, to whom, when, or how. Whereas 
all the IRBs vigorously examine and debate the 
compensation provided to research participants, 
most of the IRBs represented in this study did not 
request or receive detailed information about the 
study budget and so knew little about the amounts 
or types of researcher and institutional compensa-
tion. Members offered comments such as: “That 
[compensation for researcher] is not discussed, not 
discussed at all. It is defi nitely something that in 
our environment people don’t want to talk about. 
It is the unknown” (hospital IRB). Another member 
explained: “Totally taboo. Someday this is coming 
. . . right now you as the investigator gets this much 
money for entering and your university gets this 
much and the university likes money” (indepen-
dent IRB). A member who seemed troubled by the 
lack of regulations when dealing with researcher 
compensation explained: “This era of transparency 
is uncomfortable for an organization that doesn’t 
want that stuff [researcher compensation] known 
and for the physicians who have had the luxury 
of a relationship and contact with industry and 
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not having to be open with patients about that” 
(hospital IRB).
The data showed that these two issues—dis-
closing the commercial purposes of research and 
disclosing researcher/institutional compensation—
were diffi cult topics for all IRBs, regardless of type. 
The responses to these issues help to exemplify 
how the explicit (protecting human subjects) and 
implicit (protecting interests of researchers) goals 
that shape the IRBs’ mission can become less con-
vergent and more competitive. Members noted 
that institutional expectations, practices, and pres-
sures can complicate efforts to both support the 
researcher/institution and at the same time protect 
the subject. Members of independent or central 
IRBs explained that an in–depth exploration of 
researcher compensation would be “bad for busi-
ness” and “we can’t do it unless everyone has to.” 
As one member explained: “I can’t remember what 
it was, where we commented to each other that the 
way the regulation was written left the door open 
and didn’t leave room for us to make a comment, 
address the issue. The authority or parameters that 
we operate under didn’t give us room to question. 
I remember we said the regulations say blah, blah, 
blah, so we can only do so and so” (independent 
IRB). Members of hospital IRBs spoke of their pro-
fessional relationships with peer researchers and 
the unease associated with asking what seemed 
like personal questions. A representative comment 
was: “There are a lot of confl icts of interest for 
someone with an experimental procedure for the 
device that they want to put in a patient. And it is 
their patient. And they get paid for it. But the IRB 
doesn’t do as critical a look at that situation. It is 
the fox in charge of the hen house. You make a lot 
of money doing practice–based research. A lot.” 
Another member noted: “It is a tough spot to be in 
as a nurse. You have to gauge when to speak up. 
There are repercussions for speaking up—this is a 
very politically correct organization and the reper-
cussions get back to you. Not politically OK to ask 
questions about things like disclosure of incentives 
and you know it” (hospital IRB). Similarly, members 
of academic IRBs noted that exploring issues asso-
ciated with researcher/institutional compensation 
could jeopardize professional relationships and 
impact issues like tenure or annual personnel evalu-
ations. As one member explained, “The IRB Chair 
should be tenured and full professor and someone 
who would be hard to touch. A junior professor 
couldn’t do that. You can’t have someone without 
power” (academic IRB). Another noted that, “If it 
is important to the U, you fi nd a way to approve 
it” (academic IRB).
Members were asked if they thought research 
participants would want to be informed about 
the commercial purposes of research and about 
researcher compensation. This question seemed to 
create a conundrum. Most members reported that 
they had little knowledge of the values, expecta-
tions, beliefs, competencies, and needs of those 
whom they are charged to protect—the research 
participants. Members noted the importance of 
including community members on the IRB to 
facilitate awareness of participant perspectives, 
but also acknowledged that it is hard to truly 
assess the extent to which such involvement truly 
represents the needs of those who may ultimately 
participate in research. Some members suspected 
that participants may well want to be informed of 
commercial purposes before agreeing to enroll in 
a study. Indeed, some members reported that they 
themselves would certainly want to be informed 
of commercial purposes and researcher compensa-
tion before participating in a study. However, such 
information was not typically viewed as within the 
purview of most IRBs and so processes for disclos-
ing such information to participants were not in 
place. As one member noted when offering a sum-
mary comment about what should be disclosed and 
how and why and when, “We don’t have a way to 
asses if we protect human subjects. Everything goes 
to that point; not even the FDA audit truly looks at 
the protection. They look at our records. They ask, 
did you document A, B, and C? Not even relevancy 
is assessed by FDA” (independent IRB).
The Participant Perspective
To explore how participants view researcher com-
pensation and commercial purposes when enrolling 
What Regulators and Researchers Can Learn from IRB Members and Subjects 61
in a study, participants were asked a series of 
questions that included: “Would you want to be 
informed about researcher compensation?” “Would 
it matter to you who is paying for or sponsoring 
the study?” “Would you want to be told if a study 
was being conducted for a commercial purpose like 
extending a patent?” “Would that kind of informa-
tion infl uence your willingness to be involved?” 
“Was there anything that came as a surprise or 
was unexpected when participating in the study?” 
This series of questions came after participants 
had a chance to provide a narrative description of 
their research experience and respond to questions 
about recruitment, the consent process, their assess-
ment of risk and benefi t, and related issues such 
as the use of resources and their decision–making 
processes. The questions about purpose and com-
pensation seemed to offer participants a different 
lens with which to assess their participation. Most 
seemed quite surprised when asked if they would 
want to receive information about the compensa-
tion provided to researchers or institutions that 
conduct research. Most had never thought about 
such compensation, or were completely unaware 
that such compensation was or could be provided. 
They offered statements like: “Wow. We didn’t 
know that—they get paid for helping to run these 
studies? Really?” (participant 47); and “That never 
entered my mind that it is a possibility. . . . It’s a 
new thought to think about compensation. I guess 
I think the doctor wouldn’t get paid” (participant 
14); and “But it would not have occurred to me 
before I learned a little more about research studies 
in general. And how they are funded. As a patient, 
it would arouse skepticism. Why are you inviting 
me? What is your larger purpose?” (participant 19).
Some participants seemed to believe that if the 
researcher received compensation, the amounts 
would be minimal. One participant explained: “I 
don’t think I would ask about it. It would feel sort 
of—not my business. But I would want to know if 
the researcher was getting compensation and then I 
would be mad if I didn’t. And when there is some-
thing like that statement in the consent form—‘the 
researcher is getting compensated’—I would think 
it was like $10—not anything big. It wouldn’t occur 
to me. The way it is written, it is like they want you 
to gloss over it. Not notice it. It is a scary deal. I think 
about my parents and they are old and don’t know 
about research and could be taken advantage of. 
And if there’s a lot of money, how do they decide 
what study to suggest?”(participant 4). Another 
one said: “Oh. Oh my. Well if they get compensa-
tion, they are ethically obligated to tell about it. 
Absolutely. If you think you are signing up for this 
study and the doc is doing it out of his charitable 
response to the world that is one thing. But, if he is 
being paid to run this study that is entirely another” 
(participant 6).
Most participants (42/50) reported that they 
wanted to know about researcher compensation 
and that such information could play a role in their 
decisions to participate. The implications of provid-
ing such disclosure were not clear. Although some 
said that such compensation would not necessarily 
deter their participation, they also asserted that 
they should be told in a very clear and transparent 
manner so that they could make informed choices. 
Explained one: “People think their physicians are 
saviors. You saved me from cancer. That’s how they 
want you to see it. I would want to know if they got 
compensation for running studies. I would want 
more than the blanket statement” (participant 26). 
Refl ected another: “Docs probably should disclose 
[what they get], though they don’t. They wouldn’t 
want to disclose because they don’t want patients to 
know—it would change their thoughts on it. Some 
would think the doc wants me on this study because 
he is making money” (participant 30). Still another 
explained: “I would feel deceived if someone was 
getting an enrollment or other incentive and not tell 
me. It would make a difference who was funding 
the study. More information should be provided—a 
statement like the doctor receives compensation for 
research—it is misleading because you think it is on 
par with what is happening to you” (participant 8).
Participants also seemed quite surprised when 
asked if they wanted to be informed about the 
commercial purposes of a study such as extend-
ing patents, developing “me–too” drugs to secure 
market shares, or assessing prescription practices. 
Most seemed to believe that clinical research was 
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being conducted to further science and so benefi t 
humankind. As one person explained: “I assume 
it is on the up and up and not so that [the phar-
maceutical company] can make a million dollars 
marketing the drug. Well, it seems to me that if I 
am in the guinea pig group, I want to make sure 
it is on the up and up and I am not sacrifi cing my 
body for someone’s bottom line” (participant 13). 
Another noted: “I wouldn’t think to ask that. I’d 
never think to ask that. But I would like to know” 
(participant 20).
Indeed, 45 of the 50 participants asserted that 
they wanted to be informed about commercial 
purposes, and most stated that disclosure of such 
information could infl uence their decisions about 
participation in future research. The statements 
offered were emphatic and descriptive: “The pur-
pose of the study . . . yes, I would want to know. 
And if it was to extend the patent or something 
like that—hmmm that’s dirty. They should tell 
about something like that. Not to tell, that does 
feel deceptive. I wouldn’t want to be in that kind 
of research” (participant 4); and “The full purpose 
should be disclosed. Otherwise I feel that is dishon-
est, just playing with words, semantics. The IRB 
should never approve that kind of consent. And I 
would lose respect for an IRB that did” (participant 
5); and “Extend a patent—hmmm. Yes, I would 
defi nitely want to know that. Then they wouldn’t 
be able to do the generic drug. I would want to 
know absolutely. Absolutely” (participant 14); 
and “People should absolutely be told if they are 
trying to extend a patent. That is not to anyone’s 
benefi t. There are some good things that pharms 
come up with—but the bad side is that capitalistic 
attitude. Absolutely I want to know. Should you 
know, absolutely. We were not told anything about 
that” (participant 16); and “Of course. The patient 
should be told about the purpose and so they can 
decide” (participant 35).
As participants pondered the questions about 
disclosure of researcher compensation and com-
mercial purposes, they seemed to reevaluate some 
of their previously held beliefs about the varied 
purposes for conducting research and why clini-
cians may choose to participate. The notion that 
a clinician might receive payment when conduct-
ing research seemed to introduce the notion that 
there could also be confl icts of interest—that cli-
nicians might have some loyalties not just to the 
individual patient but to the industry or that the 
trial might not actually provide optimal personal 
clinical care. Likewise, the specter of commercial 
purposes seemed to introduce the notion that clini-
cal research, even when conducted in seemingly 
legitimate and respected settings, might have goals 
other than the betterment of humankind.
It is not clear how the disclosure of such infor-
mation during the consent process might infl uence 
participants’ decisions to enroll in research studies. 
For some, such information would not be a deter-
rent for participation. One person, commenting 
on how disclosure of commercial purposes could 
infl uence future actions noted: “Right off hand, I 
would say it wouldn’t but I may have to reconsider 
that. I’d have to think about it. I can’t come up right 
of the top of my head with what I’d do. But I am 
not sure if it would be a decision–breaker. I would 
be OK with the general concept” (participant 20). 
Another person explained: “What it would do is 
tell me that this is a drug that has been around 
and so maybe my risk would be less. So if I was 
signing up, I might think I might only be taking a 
minimal risk. So that would be reassuring. But then 
the patent issue—well, it would bother me because 
I would understand the patent game—but most 
people might not know. You get money for doing 
something that is low risk and you can do another 
one. The overall deal is that it is bad for society and 
good for the person. In the jaded world we know 
that this is done to make pharms more money” 
(participant 25). For other participants, however, the 
specter of commercial purposes would undermine 
the legitimacy of the study and could become a 
“deal breaker” in terms of their participation.
The data clearly show that most participants 
want transparent information about both issues: 
The potential commercial purposes of research 
and researcher compensation. The vast majority 
of participants also felt that it is deceptive not to 
fully disclose and that forthright information about 
these issues could certainly infl uence subsequent 
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decisions about research participation. Two com-
ments are illustrative: “Yes. I would ask more 
questions. If I didn’t know that it was available and 
not disclosed, I would trot along, never suspect-
ing anything. If I knew enough to ask if this was a 
matter of extending a patent and didn’t receive a 
satisfactory response, I would not go into a study. 
But I did not know, at the time, to ask the question” 
(participant 19); and “Yes. Absolutely. To me that 
is such a direct confl ict of interest. It seems a no 
brainer that you would have to tell people that. I 
think most people don’t understand the structure 
of how drug testing works and when they are asked 
to join a study, they wouldn’t think to ask questions 
about stuff like that” (participant 28).
Moving the Conversation Forward
The fi ndings from the two studies have identifi ed 
issues that can compromise the protection of human 
subjects and lend support to the HHS effort to 
revise the Common Rule. Questions 35 through 40 
of the ANPRM seem particularly relevant as they 
specifi cally focus on improving informed consent 
forms, an issue that was an ongoing concern for 
the IRB members who participated in the authors’ 
study. Question 40 asked whether informed consent 
would be improved if investigators were required 
to disclose in consent forms certain information 
about the fi nancial relationships they have with 
study sponsors. Our results suggest that research 
subjects are interested in knowing this information. 
However, the public comments on this question add 
another level of complexity to the debate, demon-
strating the wide range of opinion on what should, 
or should not, be disclosed to patients, and the role 
of IRBs and other committees in reviewing this 
information (U.S. HHS, 2011). The views expressed 
suggest that there is currently no consensus on 
these issues. Some commenters strongly assert that 
the investigators should be required to disclose in 
consent forms information about fi nancial relation-
ships they have with study sponsors. One com-
menter with this perspective wrote: “Researchers 
and sponsoring Institutions should fully declare all 
fi nancial and other relationships related to a study 
and its sponsors to gain and maintain public trust” 
(Sage Bionetworks, 2011).
In contrast, several comments suggested that 
research subjects may lack the sophistication to 
comprehend and assess the signifi cance of potential 
fi nancial confl icts. One commenter wrote: “The 
sponsor does not believe that investigators should 
have to disclose fi nancial relationships with spon-
sors since subjects are not capable of correctly 
interpreting this information. This information is 
already captured in the fi nancial disclosure form 
and submitted to the FDA at the time of submit-
ting a marketing application” (Boehringer Ingel-
heim Pharmaceuticals, 2011). Another stated: “No 
additions to the consent form are recommended. 
Requiring information about fi nancial relationships 
is likely to confuse rather than inform subjects about 
sponsor and investigator relationships” (Fairview 
Health Services, 2011).
A number of commenters questioned the need 
for including this requirement, noting that their 
institution currently requires such disclosure in con-
sent forms, whereas others suggest that including 
this information in the consent form is not necessary 
because the vetting of fi nancial confl ict of interest is 
handled by IRBs or confl ict of interest committees. 
As one commenter noted, “We believe institutions 
should have discretion, but the regulations should 
not mandate and determine when participants must 
be notifi ed of fi nancial interests of the investiga-
tors. This would be just another administrative 
burden added to IRB Offi ces without the hope 
for or reality of increasing participant protection. 
Institutions already require their investigators to 
disclose their fi nancial relationships through their 
Confl ict of Interest committees/process” (Arizona 
State University, 2011).
Some commenters focused on the complexity of 
the issue or suggested that no new requirements 
should be established until research is done to 
determine the need or importance of such disclo-
sures. One commenter with this perspective stated: 
“Any proposed additional elements to be included 
as part of the informed consent process, such as 
when fi nancial interests of investigators should 
be disclosed to research subjects, should only be 
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considered after further study of what form of inter-
action is most comprehensible to research subjects” 
(University of Pittsburgh, 2011).
These comments, when combined with the 
authors’ fi ndings, attest to the challenges that 
face any effort to meaningfully revise the Com-
mon Rule. The data from the IRB and the research 
participant studies show that the IRB efforts to 
achieve protection via the best possible consent 
document are consistently moderated by both the 
IRB processes and the decision–making process 
that the research participants bring to the research 
enterprise. Even the most carefully designed forms 
may be of limited utility as research participants 
seem to overlook information in the consent form 
and instead largely base their decisions on a per-
vasive level of trust—trust of the one who sug-
gests participation (trusted physician), trust in the 
system (safe and not allowed if dangerous), trust 
in the product (new gold standard), and trust in 
the outcome (personal and humanitarian good). 
The HHS comments from researchers, administra-
tors, and individuals with commercial interests in 
research suggest wide discrepancies among the 
various stakeholders’ viewpoints on the effective-
ness of current protocols and what may be impor-
tant going forward. It is critical to hear more from 
the one voice less well represented by the public 
comments—that of the research participant. The 
limited input offered from the perspective of the 
research participant may represent an important 
gap in knowledge, as fi ndings from the research 
participant study suggest that participants have 
distinct views, perspectives, and concerns on what 
constitutes full and informed consent.
Although the qualitative design of this research 
limits the generalizability of fi ndings, it has identi-
fi ed themes, concerns, concepts, and approaches 
that are relevant to discussions about the protec-
tion of human research subjects. To truly identify 
areas where protection and informed consent can 
be enhanced, we need to think deeply about the 
IRB’s mission including management of the explicit 
goal of protecting human subjects and the implicit 
goals of protecting the interests of researchers 
and advancing meritorious science. We also need 
to better understand the values, beliefs, and the 
expectations that participants bring to their deci-
sions about research participation and whether 
other information, such as information about 
researcher compensation or the reason for conduct-
ing the study, may be pivotal for the participant’s 
decision making. We need to better understand 
what researchers and administrators deem effec-
tive, reasonable and doable. In short, we need to 
continually ask ourselves how we can best hear all 
of the voices who are involved in the research enter-
prise—those who have a fi nancial, institutional, or 
professional stake and those who put their health 
and well–being on the line on behalf of science. The 
benefi ts of such inclusive conversations could be 
considerable; greater awareness and understanding 
among key stakeholders may reinforce trust and 
confi dence in the research enterprise and ultimately 
lead to a more ethically attuned research environ-
ment, one in which the participant becomes not 
just protected but informed, and not just a subject 
but a partner.
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